Blog
About

1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Treatment of Angina Pectoris Associated with Coronary Microvascular Dysfunction.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Treatment of angina pectoris associated with coronary microvascular dysfunction is challenging as the underlying mechanisms are often diverse and overlapping. Patients with type 1 coronary microvascular dysfunction (i.e. absence of epicardial coronary artery disease and myocardial disease) should receive strict control of their cardiovascular risk factors and thus receive statins and ACE-inhibitors in most cases. Antianginal medication consists of ß-blockers and/or calcium channel blockers. Second line drugs are ranolazine and nicorandil with limited evidence. Despite individually titrated combinations of these drugs up to 30 % of patients have refractory angina. Rho-kinase inhibitors and endothelin-receptor antagonists represent potential drugs that may prove useful in these patients in the future.

          Related collections

          Author and article information

          Journal
          Cardiovasc Drugs Ther
          Cardiovascular drugs and therapy
          Springer Nature America, Inc
          1573-7241
          0920-3206
          Aug 2016
          : 30
          : 4
          Affiliations
          [1 ] Department of Cardiology, Robert-Bosch-Krankenhaus, 110, 70376, Stuttgart, Germany. Peter.Ong@rbk.de.
          [2 ] Department of Cardiology, Robert-Bosch-Krankenhaus, 110, 70376, Stuttgart, Germany.
          Article
          10.1007/s10557-016-6676-z
          10.1007/s10557-016-6676-z
          27358172

          Comments

          Comment on this article